Advertisement

Cutaneous T-Cell Lymphomas in Childhood and Adolescence

  • Rein Willemze
Chapter

Abstract

Cutaneous T-cell lymphomas (CTCLs) usually affect adult and elderly patients and are rare in childhood and adolescence. CTCLs most commonly seen in children are mycosis fungoides and its variants and primary cutaneous CD30-positive lymphoproliferations, in particular lymphomatoid papulosis. Hydroa vacciniforme-like lymphoproliferative disorder and hypersensitivity reactions to mosquito bites are cutaneous manifestations of chronic active EBV infection, which are seen mainly in children and adolescents in Central and South America and Asia. Pediatric CTCLs generally have the same clinicopathologic features and clinical behavior as their adult counterparts. Most patients with juvenile mycosis fungoides present with early patch/plaque stage disease, and progression to advanced stage disease is rarely observed. Diagnosis and treatment of these rare conditions can be challenging. Clinicopathologic correlation and a multidisciplinary approach with close collaboration between pediatric oncologists, dermatologists, and pathologists are the best guarantee for correct diagnosis and adequate treatment.

Keywords

Cutaneous T-cell lymphoma Mycosis fungoides Cutaneous anaplastic large cell lymphoma Lymphomatoid papulosis Childhood 

References

  1. 1.
    Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–85.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol. 2007;143:854–9.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of hematopoietic and lymphoid tissue (Revised 4th edition). Lyon: IARC Press; 2017.Google Scholar
  4. 4.
    Tan SH, Sim CS, Ong BH. Cutaneous lymphomas other than mycosis fungoides in Singapore: a clinicopathological analysis using recent classification systems. Br J Dermatol. 2003;149:542–53.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Park JH, Shin HT, Lee DY, et al. World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphoma in Korea: a retrospective study at a single tertiary institution. J Am Acad Dermatol. 2012;67:1200–9.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Fink-Puches R, Chott A, Ardigo M, et al. The spectrum of cutaneous lymphomas in patients less than 20 years of age. Pediatr Dermatol. 2004;21:525–33.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Boccara O, Blanche S, de PY, Brousse N, Bodemer C, Fraitag S. Cutaneous hematologic disorders in children. Pediatr Blood Cancer. 2012;58:226–32.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Kempf W, Kazakov DV, Belousova IE, Mitteldorf C, Kerl K. Paediatric cutaneous lymphomas: a review and comparison with adult counterparts. J Eur Acad Dermatol Venereol. 2015;29:1696–709.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Ceppi F, Pope E, Ngan B, Abla O. Primary cutaneous lymphomas in children and adolescents. Pediatr Blood Cancer. 2016;63:1886–94.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Castano E, Glick S, Wolgast L, et al. Hypopigmented mycosis fungoides in childhood and adolescence: a long-term retrospective study. J Cutan Pathol. 2013;40:924–34.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Hodak E, Amitay-Laish I, Feinmesser M, et al. Juvenile mycosis fungoides: cutaneous T-cell lymphoma with frequent follicular involvement. J Am Acad Dermatol. 2014;70:993–1001.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Amitay-Laish I, Feinmesser M, Ben-Amitai D, et al. Juvenile onset of primary low-grade cutaneous B-cell lymphoma. Br J Dermatol. 2009;161:140–7.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Amitay-Laish I, Tavallaee M, Kim J, et al. Paediatric primary cutaneous marginal zone B-cell lymphoma: does it differ from its adult counterpart? Br J Dermatol. 2017;176:1010–20.PubMedCrossRefGoogle Scholar
  14. 14.
    Muljono A, Graf NS, Arbuckle S. Primary cutaneous lymphoblastic lymphoma in children: series of eight cases with review of the literature. Pathology (Phila). 2009;41:223–8.Google Scholar
  15. 15.
    van Doorn R, van Haselen CW, van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 2000;136:504–10.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28:4730–9.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Nanda A, AlSaleh QA, Al-Ajmi H, et al. Mycosis fungoides in Arab children and adolescents: a report of 36 patients from Kuwait. Pediatr Dermatol. 2010;27:607–13.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Yazganoglu KD, Topkarci Z, Buyukbabani N, Baykal C. Childhood mycosis fungoides: a report of 20 cases from Turkey. J Eur Acad Dermatol Venereol. 2013;27:295–300.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Laws PM, Shear NH, Pope E. Childhood mycosis fungoides: experience of 28 patients and response to phototherapy. Pediatr Dermatol. 2014;31:459–64.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Boulos S, Vaid R, Aladily TN, Ivan DS, Talpur R, Duvic M. Clinical presentation, immunopathology, and treatment of juvenile-onset mycosis fungoides: a case series of 34 patients. J Am Acad Dermatol. 2014;71:1117–26.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Heng YK, Koh MJ, Giam YC, Tang MB, Chong WS, Tan SH. Pediatric mycosis fungoides in Singapore: a series of 46 children. Pediatr Dermatol. 2014;31:477–82.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Moon HR, Lee WJ, Won CH, et al. Paediatric cutaneous lymphoma in Korea: a retrospective study at a single institution. J Eur Acad Dermatol Venereol. 2014;28:1798–804.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Tsianakas A, Kienast AK, Hoeger PH. Infantile-onset cutaneous T-cell lymphoma. Br J Dermatol. 2008;159:1338–41.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    El-Shabrawi-Caelen L, Cerroni L, Medeiros LJ, McCalmont TH. Hypopigmented mycosis fungoides: frequent expression of a CD8+ T-cell phenotype. Am J Surg Pathol. 2002;26:450–7.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Hickham PR, McBurney EI, Fitzgerald RL. CTCL in patients under 20 years of age: a series of five cases. Pediatr Dermatol. 1997;14:93–7.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Crowley JJ, Nikko A, Varghese A, Hoppe RT, Kim YH. Mycosis fungoides in young patients: clinical characteristics and outcome. J Am Acad Dermatol. 1998;38:696–701.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Quaglino P, Zaccagna A, Verrone A, Dardano F, Bernengo MG. Mycosis fungoides in patients under 20 years of age: report of 7 cases, review of the literature and study of the clinical course. Dermatology. 1999;199:8–14.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome - Update 2017. Eur J Cancer. 2017;77:57–74.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Nashan D, Faulhaber D, Stander S, Luger TA, Stadler R. Mycosis fungoides: a dermatological masquerader. Br J Dermatol. 2007;156:1–10.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Kazakov DV, Burg G, Kempf W. Clinicopathological spectrum of mycosis fungoides. J Eur Acad Dermatol Venereol. 2004;18:397–415.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Martinez-Escala ME, Gonzalez BR, Guitart J. Mycosis Fungoides variants. Surg Pathol Clin. 2014;7:169–89.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol. 2002;138:191–8.PubMedGoogle Scholar
  33. 33.
    Gerami P, Rosen S, Kuzel T, Boone SL, Guitart J. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol. 2008;144:738–46.PubMedGoogle Scholar
  34. 34.
    Lehman JS, Cook-Norris RH, Weed BR, et al. Folliculotropic mycosis fungoides: single-center study and systematic review. Arch Dermatol. 2010;146:607–13.PubMedGoogle Scholar
  35. 35.
    Wieser I, Wang C, Alberti-Violetti S, et al. Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides. Arch Dermatol Res. 2017;309:453–9.PubMedCrossRefGoogle Scholar
  36. 36.
    van Santen S, Roach RE, van Doorn R, et al. Clinical staging and prognostic factors in Folliculotropic Mycosis Fungoides. JAMA Dermatol. 2016;152:992–1000.PubMedCrossRefGoogle Scholar
  37. 37.
    Hodak E, Amitay-Laish I, Atzmony L, et al. New insights into folliculotropic mycosis fungoides (FMF): a single-center experience. J Am Acad Dermatol. 2016;75:347–55.PubMedCrossRefGoogle Scholar
  38. 38.
    Gerami P, Guitart J. The spectrum of histopathologic and immunohistochemical findings in folliculotropic mycosis fungoides. Am J Surg Pathol. 2007;31:1430–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Vergier B, Beylot-Barry M, Beylot C, et al. Pilotropic cutaneous T-cell lymphoma without mucinosis. A variant of mycosis fungoides? French Study Group of Cutaneous Lymphomas. Arch Dermatol. 1996;132:683–7.PubMedCrossRefGoogle Scholar
  40. 40.
    LeBoit PE, Abel EA, Cleary ML, et al. Clonal rearrangement of the T cell receptor beta gene in the circulating lymphocytes of erythrodermic follicular mucinosis. Blood. 1988;71:1329–33.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Boer A, Guo Y, Ackerman AB. Alopecia mucinosa is mycosis fungoides. Am J Dermatopathol. 2004;26:33–52.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Cerroni L, Fink-Puches R, Back B, Kerl H. Follicular mucinosis: a critical reappraisal of clinicopathologic features and association with mycosis fungoides and Sezary syndrome. Arch Dermatol. 2002;138:182–9.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Alikhan A, Griffin J, Nguyen N, Davis DM, Gibson LE. Pediatric follicular mucinosis: presentation, histopathology, molecular genetics, treatment, and outcomes over an 11-year period at the Mayo Clinic. Pediatr Dermatol. 2013;30:192–8.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Zvulunov A, Shkalim V, Ben-Amitai D, Feinmesser M. Clinical and histopathologic spectrum of alopecia mucinosa/follicular mucinosis and its natural history in children. J Am Acad Dermatol. 2012;67:1174–81.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Haghighi B, Smoller BR, LeBoit PE, Warnke RA, Sander CA, Kohler S. Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study. Mod Pathol. 2000;13:502–10.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Miedler JD, Kristjansson AK, Gould J, Tamburro J, Gilliam AC. Pagetoid reticulosis in a 5-year-old boy. J Am Acad Dermatol. 2008;58:679–81.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Matsuzaki Y, Kimura K, Nakano H, Hanada K, Sawamura D. Localized pagetoid reticulosis (Woringer-Kolopp disease) in early childhood. J Am Acad Dermatol. 2009;61:120–3.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Steffen C. Ketron-Goodman disease, Woringer-Kolopp disease, and pagetoid reticulosis. Am J Dermatopathol. 2005;27:68–85.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    LeBoit PE. Granulomatous slack skin. Dermatol Clin. 1994;12:375–89.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    van Haselen CW, Toonstra J, van der Putte SJ, van Dongen JJ, van Hees CL, van Vloten WA. Granulomatous slack skin. Report of three patients with an updated review of the literature. Dermatology. 1998;196:382–91.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Camacho FM, Burg G, Moreno JC, Campora RG, Villar JL. Granulomatous slack skin in childhood. Pediatr Dermatol. 1997;14:204–8.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Moreno-Gimenez JC, Jimenez-Puya R, Galan-Gutierrez M, Perez-Seoane C, Camacho FM. Granulomatous slack skin disease in a child: the outcome. Pediatr Dermatol. 2007;24:640–5.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Gokdemir G, Argon A, Sakiz D, Argon D, Koslu A. Granulomatous slack skin: report of a case with response to electron beam therapy. Med Oncol. 2008;25:178–81.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Sheng Y, Chen L, Huang Z, et al. Granulomatous slack skin: assessment of disease progression and treatment response using positron emission tomography/computed tomography. Clin Lymphoma Myeloma. 2009;9:455–8.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Tronnier M. Foreign-body-associated granulomatous slack skin in folliculotropic mycosis fungoides of childhood. J Cutan Pathol. 2009;36:578–81.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Kempf W, Ostheeren-Michaelis S, Paulli M et al. Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of thr Cutaneous Lymphoma Histopathology Task Force Group of the European Organization for Research and Treatment of Cancer (EORTC). Arch Dermatol. 2008;144:1609–17.Google Scholar
  57. 57.
    Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653–61.PubMedPubMedCentralGoogle Scholar
  58. 58.
    de Souza A, Camilleri MJ, Wada DA, Appert DL, Gibson LE, el-Azhary RA. Clinical, histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients. J Am Acad Dermatol. 2009;61:993–1000.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Karai LJ, Kadin ME, Hsi ED, et al. Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. Am J Surg Pathol. 2013;37:1173–81.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Kempf W. A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders. Semin Diagn Pathol. 2017;34:22–35.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Wada DA, Law ME, Hsi ED, et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol. 2011;24:596–605.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Nijsten T, Curiel-Lewandrowski C, Kadin ME. Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases. Arch Dermatol. 2004;140:306–12.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Miquel J, Fraitag S, Hamel-Teillac D, et al. Lymphomatoid papulosis in children: a series of 25 cases. Br J Dermatol. 2014;171:1138–46.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    de Souza A, el-Azhary RA, Camilleri MJ, Wada DA, Appert DL, Gibson LE. In search of prognostic indicators for lymphomatoid papulosis: a retrospective study of 123 patients. J Am Acad Dermatol. 2012;66:928–37.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Cordel N, Tressieres B, D’Incan M, et al. Frequency and risk factors for associated lymphomas in patients with lymphomatoid papulosis. Oncologist. 2016;21:76–83.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118:4024–35.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Bruijn MS, Horvath B, van Voorst Vader PC, Willemze R, Vermeer MH. Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch Cutaneous Lymphoma Group. Br J Dermatol. 2015;173:1319–22.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Melchers RC, Willemze R, Bekkenk MW et al. Evaluation of treatment results in multifocal primary cutaneous anaplastic large cell lymphoma: report of the Dutch Cutaneous Lymphoma Group. Br J Dermatol. 2018;179:724–31.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003;49:1049–58.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Tomaszewski MM, Moad JC, Lupton GP. Primary cutaneous Ki-1(CD30) positive anaplastic large cell lymphoma in childhood. J Am Acad Dermatol. 1999;40:857–61.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Hazneci E, Aydin NE, Dogan G, Turhan IO. Primary cutaneous anaplastic large cell lymphoma in a young girl. J Eur Acad Dermatol Venereol. 2001;15:366–7.PubMedPubMedCentralGoogle Scholar
  72. 72.
    Kumar S, Pittaluga S, Raffeld M, Guerrera M, Seibel NL, Jaffe ES. Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature. Pediatr Dev Pathol. 2005;8:52–60.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    DeCoteau JF, Butmarc JR, Kinney MC, Kadin ME. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood. 1996;87:3437–41.PubMedPubMedCentralGoogle Scholar
  74. 74.
    Kadin ME, Pinkus JL, Pinkus GS, et al. Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative. Am J Surg Pathol. 2008;32:1421–6.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Oschlies I, Lisfeld J, Lamant L, et al. ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study. Haematologica. 2013;98:50–6.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Quintanilla-Martinez L, Jansen PM, Kinney MC, Swerdlow SH, Willemze R. Non-mycosis fungoides cutaneous T-cell lymphomas: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol. 2013;139:491–514.PubMedCrossRefGoogle Scholar
  77. 77.
    Attygalle AD, Cabecadas J, Gaulard P, et al. Peripheral T-cell and NK-cell lymphomas and their mimics; taking a step forward - report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology. 2014;64:171–99.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours: pathology and genetics of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.Google Scholar
  79. 79.
    Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol. 1998;22:881–93.PubMedCrossRefGoogle Scholar
  80. 80.
    Massone C, Chott A, Metze D, et al. Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol. 2004;28:719–35.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood. 2008;111:838–45.CrossRefGoogle Scholar
  82. 82.
    Huppmann AR, Xi L, Raffeld M, Pittaluga S, Jaffe ES. Subcutaneous panniculitis-like T-cell lymphoma in the pediatric age group: a lymphoma of low malignant potential. Pediatr Blood Cancer. 2013;60:1165–70.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Pincus LB, LeBoit PE, McCalmont TH, et al. Subcutaneous panniculitis-like T-cell lymphoma with overlapping clinicopathologic features of lupus erythematosus: coexistence of 2 entities? Am J Dermatopathol. 2009;31:520–6.CrossRefGoogle Scholar
  84. 84.
    Oschlies I, Simonitsch-Klupp I, Maldyk J, et al. Subcutaneous panniculitis-like T-cell lymphoma in children: a detailed clinicopathological description of 11 multifocal cases with a high frequency of haemophagocytic syndrome. Br J Dermatol. 2015;172:793–7.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Mizutani S, Kuroda J, Shimura Y, et al. Cyclosporine A for chemotherapy-resistant subcutaneous panniculitis-like T cell lymphoma with hemophagocytic syndrome. Acta Haematol. 2011;126:8–12.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Mehta N, Wayne AS, Kim YH, et al. Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations. Clin Lymphoma Myeloma Leuk. 2012;12:20–5.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Kawachi Y, Furuta J, Fujisawa Y, Nakamura Y, Ishii Y, Otsuka F. Indolent subcutaneous panniculitis-like T cell lymphoma in a 1-year-old child. Pediatr Dermatol. 2012;29:374–7.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Bittencourt AL, Vieira M, Carvalho EG, Cunha C, Araujo I. Subcutaneous Panniculitis-Like T-Cell Lymphoma (SPTL) in a Child with Spontaneous Resolution. Case Rep Oncol Med. 2011;2011:639240.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Johnston EE, LeBlanc RE, Kim J, et al. Subcutaneous panniculitis-like T-cell lymphoma: Pediatric case series demonstrating heterogeneous presentation and option for watchful waiting. Pediatr Blood Cancer. 2015;62:2025–8.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Tokura Y, Ishihara S, Tagawa S, Seo N, Ohshima K, Takigawa M. Hypersensitivity to mosquito bites as the primary clinical manifestation of a juvenile type of Epstein-Barr virus-associated natural killer cell leukemia/lymphoma. J Am Acad Dermatol. 2001;45:569–78.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Rodriguez-Pinilla SM, Barrionuevo C, Garcia J, et al. EBV-associated cutaneous NK/T-cell lymphoma: review of a series of 14 cases from peru in children and young adults. Am J Surg Pathol. 2010;34:1773–82.CrossRefGoogle Scholar
  92. 92.
    Iwatsuki K, Xu Z, Takata M, et al. The association of latent Epstein-Barr virus infection with hydroa vacciniforme. Br J Dermatol. 1999;140:715–21.CrossRefGoogle Scholar
  93. 93.
    Sangueza M, Plaza JA. Hydroa vacciniforme-like cutaneous T-cell lymphoma: clinicopathologic and immunohistochemical study of 12 cases. J Am Acad Dermatol. 2013;69:112–9.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Barrionuevo C, Anderson VM, Zevallos-Giampietri E, et al. Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol. 2002;10:7–14.CrossRefGoogle Scholar
  95. 95.
    Kawa K, Okamura T, Yagi K, Takeuchi M, Nakayama M, Inoue M. Mosquito allergy and Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease. Blood. 2001;98:3173–4.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Kimura H, Ito Y, Kawabe S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood. 2012;119:673–86.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Rein Willemze
    • 1
  1. 1.Department of DermatologyLeiden University Medical CenterLeidenThe Netherlands

Personalised recommendations